Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J0751 · per 200 mg/25 mg

Hiv prep, ftc/taf 200/25mg

Products billed under this code include Descovy.

Payment limit per 200 mg/25 mg, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0751

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Descovy Gilead Sciences, Inc 61958-2002-01 30 $2,248.23
Descovy Gilead Sciences, Inc 61958-2002-02 30 $2,248.23

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $74.941 +$3.514 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted September 17, 2026
3Q26 $71.427 −$0.008 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted September 15, 2026
2Q26 $71.435 +$0.108 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted September 15, 2026
1Q26 $71.327 +$0.003 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted September 15, 2026
4Q25 $71.324 +$0.05 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted September 8, 2026
3Q25 $71.274 +$0.002 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted March 10, 2026
2Q25 $71.272 −$0.017 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted March 10, 2026
1Q25 $71.289 – 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted December 19, 2025
4Q24 N/A – 200 mg/25 mg Hiv prep, ftc/taf 200/25mg v1, posted June 11, 2025

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files